Literature DB >> 11115234

Epilepsy and the immune system.

J A Aarli1.   

Abstract

OBJECTIVE: To discuss evidence that immune mechanisms are involved in the pathogenesis of some forms of epilepsy. DATA SOURCES: Computerized data sources and published indexes and articles. STUDY SELECTION: Published reports showing disorders of the immune system in patients with epilepsy and in animals with experimental epilepsy. DATA SYNTHESIS: Rasmussen encephalitis is an example of an autoimmune disorder of the central nervous system. Serum samples of patients with this disease contain antibodies to the glutamate receptor GluR3, and immunization of animals with GluR3 induces a disorder resembling the human disease. There are still few data to prove that immune mechanisms are involved in the pathogenesis of intractable childhood epilepsies other than Rasmussen encephalitis. Epilepsy is more common in patients with systemic lupus erythematosus who have antiphospholipid antibodies, and it is possible that these antibodies can lead to immune-mediated cortical damage. Immune defects in patients with epilepsy may occur as a consequence of long-term antiepileptic treatment or may represent a genetic coupling to the convulsive disorder.
CONCLUSION: The finding of an immunological basis may offer new modalities for the treatment of selected cases of intractable partial epilepsies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115234     DOI: 10.1001/archneur.57.12.1689

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

Review 1.  The role of inflammation in epilepsy.

Authors:  Annamaria Vezzani; Jacqueline French; Tamas Bartfai; Tallie Z Baram
Journal:  Nat Rev Neurol       Date:  2010-12-07       Impact factor: 42.937

2.  Reactions of the immune system in epilepsy.

Authors:  Inimioara Mihaela Cojocaru; Manole Cojocaru
Journal:  Maedica (Buchar)       Date:  2010-07

3.  Epileptogenesis due to glia-mediated synaptic scaling.

Authors:  Cristina Savin; Jochen Triesch; Michael Meyer-Hermann
Journal:  J R Soc Interface       Date:  2008-11-04       Impact factor: 4.118

4.  The effects of interleukin-10 on the development of epileptiform activity in the hippocampus induced by transient hypoxia, bicuculline, and electrical kindling.

Authors:  O V Godukhin; S G Levin; E Yu Parnyshkova
Journal:  Neurosci Behav Physiol       Date:  2009-07-21

5.  The protective action of tumor necrosis factor alpha (TNF-alpha) on the hypersensitivity of pyramidal neurons in field CA1 in rat hippocampal slices induced by episodes of hypoxia.

Authors:  S G Levin; M E Burkovetskaya; O V Godukhin
Journal:  Neurosci Behav Physiol       Date:  2008-07-08

6.  Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood.

Authors:  P M C Callenbach; C M Jol-Van Der Zijde; A T Geerts; W F M Arts; C A Van Donselaar; A C B Peters; H Stroink; O F Brouwer; M J D Van Tol
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

7.  Protective effects of interleukin-10 on the development of epileptiform activity evoked by transient episodes of hypoxia in rat hippocampal slices.

Authors:  S G Levin; O V Godukhin
Journal:  Neurosci Behav Physiol       Date:  2007-06

8.  Effect of anti-epileptic drugs on serum level of IgG subclasses.

Authors:  Mahmoud-Reza Ashrafi; Seyed-Ahmad Hosseini; Mohammad Biglari; Sarah Abolmaali; Reza Azizi Malamiri; Hoda Mombeini; Zahra Pourpak; Narges Saladjegheh; Nima Rezaei; Azam Samadian; Asghar Aghamohammadi
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

9.  Treatment of Lennox-Gastaut syndrome: overview and recent findings.

Authors:  Kenou van Rijckevorsel
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  TNF-overexpression in Borna disease virus-infected mouse brains triggers inflammatory reaction and epileptic seizures.

Authors:  Katharina Kramer; Dirk Schaudien; Ulrich L M Eisel; Sibylle Herzog; Jürgen A Richt; Wolfgang Baumgärtner; Christiane Herden
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.